A retrospective cohort study analyzed 29 patients with peritoneal sarcomatosis who underwent cytoreductive surgery (CRS) with bidirectional intraoperative chemotherapy (BDIC) using intravenous ifosfamide and hyperthermic intraperitoneal chemotherapy (HIPEC). The overall survival rates at 6, 12, 24, and 48 months after CRS/BDIC were 93.1%, 89.2%, 81.4%, and 73.3%, respectively. Disease recurrence rates were 15% at 6 […]
Category: Cytoreductive Surgery & Peritoneum
Defining Success in Colorectal Peritoneal Metastasis Surgery: International Consensus and Improved Survival
An international consensus has been reached on the definition of textbook oncologic outcomes (TOO) in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastasis. The TOO parameters for CRS/HIPEC in this context include absence of certain complications, achievement of complete cytoreduction, and no contraindications for chemotherapy. A study cohort of 251 patients […]
Drug Response Heterogeneity Found in Patients Undergoing CRS/HIPEC for Nongynecologic Cancers
Among patients undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for nongynecologic cancers, intra- and interpatient drug response heterogeneity was observed. Researchers generated patient-derived tumor organoids (PDTOs) and conducted in vitro drug screens to assess drug response. PDTOs were successfully generated from 13 out of 23 patients, and drug screen results were obtained in as […]
Predictive Factors for Early Recurrence in Metastatic Colorectal Cancer Treated with Combined Liver Resection and HIPEC
The study aimed to identify predictive factors for early recurrence and survival outcomes in colorectal cancer patients with liver and peritoneal metastases who underwent combined liver resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy. The results showed that patients with advanced primary tumors (PT4 and/or PN2 status) had a higher risk of early recurrence, while retroperitoneal […]
Predictive Factors for Early Recurrence in Metastatic Colorectal Cancer Treated with Combined Liver Resection and HIPEC
The study aimed to identify predictive factors for early recurrence and survival outcomes in colorectal cancer patients with liver and peritoneal metastases who underwent combined liver resection, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy. The results showed that patients with advanced primary tumors (PT4 and/or PN2 status) had a higher risk of early recurrence, while retroperitoneal […]
Textbook Oncologic Outcomes Enhance Survival in CRS and HIPEC for Colorectal Peritoneal Metastasis
Expert consensus was achieved on the definition of textbook oncologic outcomes (TOO) in cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastasis. The consensus criteria included the absence of unplanned re-operations, severe postoperative complications, unplanned readmissions, 90-day postoperative mortality, and contraindications for chemotherapy within 12 weeks. In a cohort of 251 patients, […]
Preoperative 18F-FDG PET/CT Associated with Pathological Tumor Grade in Pseudomyxoma Peritonei
The clinical effectiveness of preoperative 18F-FDG PET/CT in predicting pathological tumor grade in patients with pseudomyxoma peritonei (PMP) originating from the appendix was evaluated in this retrospective cohort study. The study found that high-grade PMP patients had a significantly higher median standardized uptake value (SUVmax) on 18F-FDG PET/CT compared to low-grade patients. The highest area […]
Extent of Surgery Found to Impact Gastrointestinal Function in Patients Undergoing CRS and HIPEC
This study investigated the impact of the extent of surgery on late adverse effects (LAEs) in patients undergoing cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The study found that patients undergoing extensive CRS experienced persistent impaired gastrointestinal function in terms of diarrhea, compared to those undergoing less extensive surgery. However, the levels of other […]
Financial toxicity risk among patients undergoing CRS-HIPEC: Study reveals one-third at risk
Researchers conducted a retrospective cohort study on 163 patients who underwent cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) between 2016 and 2022. They found that 31.9% of patients were at risk of financial toxicity, with higher out-of-pocket expenditures and lower income quartiles being significant risk factors. The median out-of-pocket expenditure for at-risk patients was $5000, […]
Long-term Survival in Patients with Colorectal Peritoneal Carcinomatosis Treated with CRS/HIPEC
Actual 5-year survival rates after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for patients with peritoneal carcinomatosis (PC) of colorectal origin were reported in this study. A total of 103 patients were analyzed, with a median follow-up of survivors at 88 months. The 5-year overall survival (OS) was 36%, and the median OS was 42.5 […]